AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AITB
CUSIPN/A
Phone972-8684-3313
Debt
Debt-to-Equity RatioN/A
Current Ratio1.38
Quick Ratio1.38
Price-To-Earnings
Trailing P/E Ratio-1.20
Forward P/E Ratio-5.37
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($1.37) per share
Price / Book-2.63
Profitability
EPS (Most Recent Fiscal Year)($3.01)
Net Income$-18,040,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-273.76%
Miscellaneous
Employees12
Outstanding Shares8,410,000
Market Cap$27.32 million
AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions
What is AIT Therapeutics' stock symbol?
AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."
How were AIT Therapeutics' earnings last quarter?
AIT Therapeutics Inc (OTCMKTS:AITB) released its quarterly earnings data on Tuesday, August, 14th. The company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.14. View AIT Therapeutics' Earnings History.
When is AIT Therapeutics' next earnings date?
What price target have analysts set for AITB?
2 brokerages have issued 12 month price targets for AIT Therapeutics' stock. Their forecasts range from $16.00 to $16.00. On average, they expect AIT Therapeutics' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price. View Analyst Price Targets for AIT Therapeutics.
What is the consensus analysts' recommendation for AIT Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AIT Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AIT Therapeutics.
Who are some of AIT Therapeutics' key competitors?
Some companies that are related to AIT Therapeutics include Sensus Healthcare (SRTS), Motus GI (MOTS), Invuity (IVTY), CAS Medical Systems (CASM), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), Repro-Med Systems (REPR), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Restoration Robotics (HAIR), Nephros (NEPH), Valeritas (VLRX) and Presbia (LENS).
Who are AIT Therapeutics' key executives?
AIT Therapeutics' management team includes the folowing people:
- Mr. Steven Adam Lisi, CEO & Chairman (Age 47)
- Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 44)
- Mr. David Grossman, Sec. & Director (Age 43)
- Mr. Stephen J. DiPalma, Chief Financial Officer (Age 59)
- Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
Has AIT Therapeutics been receiving favorable news coverage?
Headlines about AITB stock have trended somewhat positive on Saturday, Accern reports. The research group identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AIT Therapeutics earned a news and rumor sentiment score of 0.02 on Accern's scale. They also assigned media coverage about the company an impact score of 46.37 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for AIT Therapeutics.
How do I buy shares of AIT Therapeutics?
Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AIT Therapeutics' stock price today?
One share of AITB stock can currently be purchased for approximately $3.60.
How big of a company is AIT Therapeutics?
AIT Therapeutics has a market capitalization of $27.32 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe.
How can I contact AIT Therapeutics?
AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.
MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.
